These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22385024)

  • 21. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
    Daimon T; Zohar S; O'Quigley J
    Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semiparametric Bayesian joint modeling of a binary and continuous outcome with applications in toxicological risk assessment.
    Hwang BS; Pennell ML
    Stat Med; 2014 Mar; 33(7):1162-75. PubMed ID: 24123309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Model uncertainty and model averaging in the estimation of infectious doses for microbial pathogens.
    Moon H; Kim SB; Chen JJ; George NI; Kodell RL
    Risk Anal; 2013 Feb; 33(2):220-31. PubMed ID: 22681783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
    Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
    Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian dose-response analysis for epidemiological studies with complex uncertainty in dose estimation.
    Kwon D; Hoffman FO; Moroz BE; Simon SL
    Stat Med; 2016 Feb; 35(3):399-423. PubMed ID: 26365692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
    Marino DJ; Starr TB
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Model-averaged benchmark concentration estimates for continuous response data arising from epidemiological studies.
    Noble RB; Bailer AJ; Park R
    Risk Anal; 2009 Apr; 29(4):558-64. PubMed ID: 19144062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Some statistical implications of dose uncertainty in radiation dose-response analyses.
    Schafer DW; Gilbert ES
    Radiat Res; 2006 Jul; 166(1 Pt 2):303-12. PubMed ID: 16808615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian optimal designs for a quantal dose-response study with potentially missing observations.
    Baek I; Zhu W; Wu X; Wong WK
    J Biopharm Stat; 2006; 16(5):679-93. PubMed ID: 17037265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
    Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hierarchical dose-response modeling for high-throughput toxicity screening of environmental chemicals.
    Wilson A; Reif DM; Reich BJ
    Biometrics; 2014 Mar; 70(1):237-46. PubMed ID: 24397816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods for assessing uncertainty in fundamental assumptions and associated models for cancer risk assessment.
    Small MJ
    Risk Anal; 2008 Oct; 28(5):1289-308. PubMed ID: 18844862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Precautionary Principle and statistical approaches to uncertainty.
    Keiding N; Budtz-Jørgensen E
    Int J Occup Med Environ Health; 2004; 17(1):147-51. PubMed ID: 15212218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the use of hierarchical probabilistic models for characterizing and managing uncertainty in risk/safety assessment.
    Kodell RL; Chen JJ
    Risk Anal; 2007 Apr; 27(2):433-7. PubMed ID: 17511709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semiparametric Bayesian analysis of case-control data under conditional gene-environment independence.
    Mukherjee B; Zhang L; Ghosh M; Sinha S
    Biometrics; 2007 Sep; 63(3):834-44. PubMed ID: 17489972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.